A systematic review investigated cutaneous adverse events (AEs) associated with semaglutide, liraglutide, and tirzepatide. The study aimed to characterize the spectrum, frequency, and clinical characteristics of these AEs, focusing on their established use in obesity and diabetes management. A literature search was conducted across MEDLINE, Embase, and Web of Science, including clinical trials, observational studies, pharmacovigilance studies, and case reports. One hundred and one studies were included, detailing skin-related manifestations linked to the three agents. Cutaneous AEs ranged from mild to severe, encompassing injection-site reactions, dysesthesia, and rarer immune-mediated disorders.
Injection-site reactions, particularly erythema, pruritus, and hemorrhage, were most frequently reported with tirzepatide, followed by liraglutide, and less commonly with semaglutide, often dependent on dosage. Dysesthesia was most strongly associated with semaglutide, occurring at approximately 5% with standard doses and up to 20% with high-dose formulations. Other uncommon reactions included angioedema, hypersensitivity reactions, autoimmune blistering diseases, drug eruptions, vasculitis, and severe cutaneous reactions.
The findings indicate that while most cutaneous AEs are mild and manageable, there are clinically relevant differences in the frequency and nature of these reactions among the three GLP-1 RA agents. Recognition of these common and uncommon skin manifestations may aid in earlier diagnosis, support treatment adherence, and potentially mitigate adverse outcomes.